Tags

Type your tag names separated by a space and hit enter

Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses.
J Endocrinol 2006; 190(1):151-6JE

Abstract

The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 microg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 +/- 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH <or=2 mIU/l. Group S2 (n = 48, mean TPOAb = 803.9 +/- 483.8 IU/ml) received 200 microg L-selenomethionine per day, orally for 3 months, and group C (n = 40, mean TPOAb = 770.3 +/- 406.2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (n = 20) went on taking L-selenomethionine 200 microg/day, while others (group S21) lowered the dose to 100 microg/day. (3) 12 patients of group S22 (group S222) went on taking L-selenomethionine 200 microg/day, while 12 patients of group S21 (S212) increased the dose to 200 microg/day. Serum titers of TPOAb decreased significantly in group S2 (26.2%, P < 0.001), group S22 (23.7%, P < 0.01) and group S212 (30.3%, P < 0.01). There were no significant changes in group C and group S222 (P > 0.05). TPOAb titers increased significantly in group S21 (38.1%, P < 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%, P < 0.01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 microg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time.

Authors+Show Affiliations

Thyroidology Unit, Department of Nuclear Medicine, GATA Haydarpasa, Istanbul, Turkey. otturker@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16837619

Citation

Turker, Omer, et al. "Selenium Treatment in Autoimmune Thyroiditis: 9-month Follow-up With Variable Doses." The Journal of Endocrinology, vol. 190, no. 1, 2006, pp. 151-6.
Turker O, Kumanlioglu K, Karapolat I, et al. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol. 2006;190(1):151-6.
Turker, O., Kumanlioglu, K., Karapolat, I., & Dogan, I. (2006). Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. The Journal of Endocrinology, 190(1), pp. 151-6.
Turker O, et al. Selenium Treatment in Autoimmune Thyroiditis: 9-month Follow-up With Variable Doses. J Endocrinol. 2006;190(1):151-6. PubMed PMID: 16837619.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. AU - Turker,Omer, AU - Kumanlioglu,Kamil, AU - Karapolat,Inanc, AU - Dogan,Ismail, PY - 2006/7/14/pubmed PY - 2006/8/17/medline PY - 2006/7/14/entrez SP - 151 EP - 6 JF - The Journal of endocrinology JO - J. Endocrinol. VL - 190 IS - 1 N2 - The aim of this study is to investigate the long-term (9 months) effects of variable doses (200/100 microg/day) of L-selenomethionine on autoimmune thyroiditis (AIT) and the parameters affecting the success rate of this therapy. The present study was designed in three steps: (1) 88 female patients with AIT (mean age = 40.1 +/- 13.3 years) were randomized into two groups according to their initial serum TSH, thyroid peroxidase antibody (TPOAb) concentrations, and age. All the patients were receiving L-thyroxine to keep serum TSH <or=2 mIU/l. Group S2 (n = 48, mean TPOAb = 803.9 +/- 483.8 IU/ml) received 200 microg L-selenomethionine per day, orally for 3 months, and group C (n = 40, mean TPOAb = 770.3 +/- 406.2 IU/ml) received placebo. (2) 40 volunteers of group S2 were randomized into two age- and TPOAb-matched groups. Group S22 (n = 20) went on taking L-selenomethionine 200 microg/day, while others (group S21) lowered the dose to 100 microg/day. (3) 12 patients of group S22 (group S222) went on taking L-selenomethionine 200 microg/day, while 12 patients of group S21 (S212) increased the dose to 200 microg/day. Serum titers of TPOAb decreased significantly in group S2 (26.2%, P < 0.001), group S22 (23.7%, P < 0.01) and group S212 (30.3%, P < 0.01). There were no significant changes in group C and group S222 (P > 0.05). TPOAb titers increased significantly in group S21 (38.1%, P < 0.01). A significant decrease in thyroglobulin antibody titers was only noted in group S2 (5.2%, P < 0.01). L-selenomethionine substitution suppresses serum concentrations of TPOAb in patients with AIT, but suppression requires doses higher than 100 microg/day which is sufficient to maximize glutathione peroxidase activities. The suppression rate decreases with time. SN - 0022-0795 UR - https://www.unboundmedicine.com/medline/citation/16837619/full_citation L2 - https://joe.bioscientifica.com/doi/10.1677/joe.1.06661 DB - PRIME DP - Unbound Medicine ER -